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PURPOSE. To compare the thickness of all retinal layers between a nondiabetic group and
diabetic patients without diabetic retinopathy (DR).
METHODS. Cross-sectional study, in which all subjects underwent an ophthalmic examination
including optical coherence tomography. After automatic retinal segmentation, each retinal
layer thickness (eight separate layers and overall thickness) was calculated in all nine Early
Treatment Diabetic Retinopathy Study (ETDRS) areas. The choroidal thickness (CT) also was
measured at five locations. Generalized additive regression models were used to analyze the
data.
RESULTS. A total of 175 patients were recruited, 50 nondiabetic subjects and 125 diabetic
patients without DR, stratified into three groups according to diabetes duration: group I (<5
years, n ¼ 55), group II (5–10 years, n ¼ 39), and group III (>10 years, n ¼ 31). Overall,
groups I and III of diabetic patients had a decrease in the photoreceptor layer (PR) thickness,
when compared with the nondiabetic subjects in six ETDRS areas (P < 0.0007). Patients with
more recent diagnosis (group I) had thinner PR than those with moderate duration (group II).
Interestingly, patients with longer known disease (group III) had the thinnest PR values. There
were no overall differences in the remaining retinal parameters.
CONCLUSIONS. Retinal thickness profile is not linear throughout disease duration. Even in the
absence of funduscopic disease, PR layer in diabetic patients seems to differ from nondiabetic
subjects, thus suggesting that some form of neurodegeneration may take place before clinical
signs of vascular problems arise.
Keywords: diabetic retinopathy, optical coherence tomography, retinal layers,
neurodegeneration
Diabetes mellitus (DM) is increasing worldwide and,accordingly, diabetic retinopathy (DR) is the leading cause
of legal blindness among working-aged adults.1 Of 415 million
people worldwide living with diabetes in 2015, more than one-
third will develop DR in their lifetime.2 More than 93 million
people currently suffer some sort of eye damage from diabetes.3
In Portugal, the PREVADIAB study found a diabetes
prevalence of 11.7%.4 If ‘‘pre-diabetes’’ is also considered, then
approximately one-third (34.9%) of the population aged 20 to
79 years is affected.4 The RETINODIAB study, an epidemiologic
study that determines the prevalence and progression inci-
dence rates of DR based on a national screening community
program in Portugal, identified a 16.3% prevalence rate of DR
and a 4.6% incidence rate of any DR in the first year, in patients
without retinopathy at baseline.5,6
The International Clinical Classification of DR is based in the
observation of microvascular changes. The first recognizable
vascular abnormalities are microaneurysms and small hemor-
rhages, followed by more severe signs of vascular leakage, such
as hard exudates and larger hemorrhages; vascular dropout,
such as cotton wool spots; and more widespread hemorrhages
and neovascularizations.7 However, retinal neurodegenerative
changes have been described as including apoptosis of several
populations of retinal cells (photoreceptors, bipolar cells,
ganglion cells, and astrocytes) with consequent reduction in
thickness of the different retinal layers, in the earliest stages of
DR or even when DR cannot be detected by ophthalmologic
examination.8–11
Recently, optical coherence tomography (OCT) has been
introduced into clinical practice as the most noninvasive and
objective method to visualize the retina, showing an amount of
detail that resembles histological specimens.12,13 Initially, OCT
was applied to detect complications of DR (edema macular or
epiretinal membrane).14 Later on, it allowed quantitative and
qualitative measurements of retinal thickness and segmentation
of all intraretinal layers.15–18 The new Spectralis spectral-
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domain (SD)-OCT automatic segmentation software (software
version 6.0; Heidelberg Engineering, Heidelberg, Germany)
demonstrated excellent repeatability and reproducibility of
each of the eight individual retinal layer thickness measure-
ments.19 Potentially, OCT might detect early retinal changes,
and thus help define which diabetic patients may be at risk to
develop DR. Ultimately, it could be used to plan preventive
therapy before the development of vascular lesions detectable
by ophthalmoscopy.20 However, until now, the smaller scale,
mostly pilot studies or only focusing on specific retinal layers
on this topic in OCT image analysis did not show a temporal
relationship between DM duration or arising DR and the
changes observed in retinal layers.
The present study aimed to address this unmet need, by
comparing the thickness of all retinal layers, measured with SD-




This cross-sectional study was conducted at the Ophthalmol-
ogy Department of the Central Lisbon Hospital Center,
between October and December of 2014. Two groups of
patients were recruited: group 1 with 50 nondiabetic subjects,
and group 2, with 125 type 2 diabetic patients without DR,
classified according to diabetes duration: group I (<5 years),
group II (5–10 years), and group III (>10 years). Per protocol,
the diagnosis of type 2 DM was made following the guidelines
of the Portuguese General Health Direction.21 The inclusion
criteria were to be a type 2 diabetic patient without DR, with
normotensive eyes, and with ability to understand the study.
The exclusion criteria were the following: refractive error >5
diopters or/and axial length >25 mm in the studied eye,
known diagnosis of DR or other retinal diseases, glaucoma or
ocular hypertension, uveitis, neurodegenerative disease, and
significant media opacities that precluded fundus imaging.
The study was approved by our institutional ethics
committee and informed consent was obtained from patients.
The principles of the Declaration of Helsinki were respected.
The ophthalmological examination included determination
of best-corrected visual acuity with Snellen scale and after
conversion to logMar, anterior segment examination, Gold-
mann applanation tonometry and dynamic contour tonometry
with Pascal digital tonometer, indirect ophthalmoscopy, and
ultrasonic biometry. Last, an SD-OCT was obtained and,
randomly, one eye of each subject was included in this study.
Spectral-Domain OCT Imaging and Layer
Segmentation
Tomographic images were obtained using the Spectralis SD-
OCT (software version 6.0; Heidelberg Engineering), after
pupillary dilation, by a single, well-trained technician (G.A.), as
described previously.22 Only good-quality scans with well-
focused images, without overt misalignment, continuous scan
patterns without missing or blank areas, without artifacts, and
a signal strength better than 20 (40¼maximum) were included
in the analyses. The fast macular thickness OCT protocol was
performed with measurements 20 3 20-degree raster scans
(consisting of 25 high-resolution scans). The automatic real-
time function was set to nine frames per B-scan. An internal
fixation light was used to center the scanning area on the fovea
while the eye-tracking system was activated.
The new Spectralis automatic segmentation software was
used to obtain individual retinal layer thickness measurements
including overall retinal thickness (RT), retinal nerve fiber layer
(RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL),
inner nuclear layer (INL), outer plexiform layer (OPL), outer
nuclear layer (ONL), retinal pigment epithelium (RPE), and
photoreceptor layer (PR) (Fig. 1). The OCT images obtained by
a technician were assessed by an ophthalmologist (J.F.) masked
to the patients’ diagnosis, that verified the automatic segmen-
FIGURE 1. Retinal layer segmentation.
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tation and corrected with manual segmentation when it was
not defined correctly.
In all layers, the thickness values were calculated for the
nine Early Treatment Diabetic Retinopathy Study (ETDRS)
areas.23 An ETDRS plot consists of three concentric rings of 1-,
3-, and 6-mm diameter centered at the fovea. The two outer
rings are divided into quadrants by two intersecting lines. Each
sector was designated C, S3, S6, T3, T6, I3, I6, N3, and N6,
according to Figure 2. The ETDRS grid was positioned
automatically by the Spectralis OCT software, enabling the
capture and extraction of the macular thickness values.
The fast macular thickness OCT protocol scans were then
again performed in enhanced depth imaging mode according
to the previously reported method.24 The choroidal thickness
(CT) was manually measured from the outer portion of the
hyperreflective line (corresponding to the RPE) to the
hyporeflective line (corresponding to the sclerochoroidal
interface). These measurements were made in the subfoveal
choroid and at 1000 lm superior, inferior, nasal, and temporal
of the fovea (five locations).
Statistical Analysis
Demographics and clinical characteristics of patients were
described using the mean (SD) or median (interquartile range:
25th percentile–75th percentile) for continuous variables, and
the frequencies (percentages) for categorical variables. Gener-
alized additive regression models were used to identify the
variables that explain the variability of thickness of retinal
layers considering diabetic and nondiabetic groups. All the
multivariable regression models included age, IOP–Pascal, axial
length, and sex to adjust the association among the four
groups, classified according to diabetes duration, and the layer
thickness. The continuous covariates were modeled with
splines due to their nonlinear association with the thickness
of all retinal layers. In particular, multivariable regression
models of RPE and PR layers in sectors C, S3, I3, N3, and T3,
also considered the variable CT subfoveal, 1000 lm superior,
inferior, nasal, and temporal of the fovea, respectively.
Normality assumption of the residuals was verified using
Kolmogorov-Smirnov goodness-of-fit test. A level of significance
of a¼0.05 was considered. Bonferroni adjustment for multiple
testing was applied. Data were analyzed using the Statistical
Package for the Social Science for Windows (released 2013,
IBM SPSS Statistics for Windows, Version 22.0; IBM Corp.,
Armonk, NY, USA) and R (R: A Language and Environment for
Statistical Computing, R Core Team, 2014; R Foundation for
Statistical Computing, Vienna, Austria, http://www.R-project.
org.)
RESULTS
Patient Demographics and Clinical Characteristics
A total of 125 diabetic patients with type 2 DM without DR (63
males), and 50 nondiabetic subjects (20 males), were included
in this study. The diabetic patients were classified into three
groups, according to the duration of diabetes: group I (up to 5
years, n ¼ 55), group II (5–10 years, n ¼ 39), and group III
(more than 10 years, n ¼ 31). The remaining demographic,
FIGURE 2. Representative Spectralis SD-OCT scans of macular
thickness map (ETDRS protocol).
TABLE 1. Demographic and Clinical Characteristics of the Patients by Group
Clinical Characteristics
Diabetic Patients, n ¼ 125
Nondiabetic Subjects,
n ¼ 50Group I, n ¼ 55 Group II, n ¼ 39 Group III, n ¼ 31
Diabetes duration, y <5 5–10 >10
Male sex, n (%) 26 (47) 23 (59) 14 (45) 20 (40)
Age, y 65.82 (9.88) 66.95 (10.14) 68.74 (6.97) 69.18 (8.55)
BCVA, logMAR 0.04 (0.07) 0.06 (0.13) 0.07 (0.10) 0.02 (0.05)
IOP–Goldmann, mm Hg 15.73 (3.08) 16.80 (2.98) 16.61 (3.14) 14.79 (2.76)
IOP–Pascal, mm Hg 19.03 (3.19) 19.02 (4.08) 19.07 (3.60) 18.25 (3.10)
OPA 2.80 (2.20–4.50) 2.50 (2.30–3.20) 3.20 (2.30–4.50) 3.10 (2.40–3.95)
Spherical equivalent 0.50 (0.00–1.50) 0.38 (0.13–1.50) 0.50 (0.38–1.63) 0.31 (1.00–1.56)
Axial length, mm 23.01 (0.82) 23.16 (0.81) 23.22 (0.78) 22.51 (1.12)
State of lens–phakic, n (%) 53 (96) 37 (95) 29 (94) 41 (82)
Mean arterial pressure, mm Hg 97.00 (91.00–110.00) 97.00 (90.00–104.00) 99.00 (93.00–109.00) 97.50 (92.75–105.00)
HbA1c, % 6.20 (5.80–6.80) 6.40 (6.00–7.20) 6.80 (6.30–7.50) –
Glycemia, mg/dL 125.00 (114.00–145.00) 142.00 (122.00–161.00) 153.00 (133.00–168.00) –
Results are expressed as mean (SD) or median (interquartile range: 25th percentile–75th percentile). BCVA, best-corrected visual acuity; IOP,
intraocular pressure; OPA, ocular pulse amplitude.
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clinical and ophthalmologic characteristics are summarized in
Table 1, and mean retinal layer thicknesses of groups are
presented in Figure 3.
Analysis of Retinal Layer Thickness
In multivariable regression models, after adjusting for age, sex,
IOP, and axial length, and correcting for multiple testing, no
difference in the overall RT thickness throughout the ETDRS
areas was found. Interestingly, the patterns of layer distribution
were not the same in the two samples.
An exploratory analysis of the RT data showed a thicker
RNFL, INL, and RPE in diabetic patients when compared with
controls. This increase reached statistical significance in only a
small number of locations (see detailed locations in Supple-
mentary Tables S1–S3, for multivariable regression model
results for RNFL, INL, and RPE thickness).
Interestingly, the PR layer was the most consistent finding,
with a smaller thickness in diabetic patients when compared
with their nondiabetic controls (Table 2). Nevertheless, the
pattern of thickness in this layer differs with disease duration.
Once we stratified diabetic patients according to this
parameter, the thinner layers could be found in patients with
both an early (group I) and longer known diabetes diagnosis
(group III) (P < 0.001). On the other hand, the thinning in PR
in diabetic patients with moderate duration (group II) did not
reach statistical significance when compared with the healthy
controls (Table 2).
The remaining layers (ONL, OPL, INL, and GCL) showed an
overall tendency toward a thicker layer in diabetic retinas
when compared with nondiabetic patients, but did not reach
statistical significance.
DISCUSSION
This cross-sectional study used SD-OCT to compare the retinal
layer thickness between nondiabetic subjects and type 2
diabetic patients without DR and with different DM duration.
Overall, the current analysis revealed a significant thinning of
the PR layer in diabetic patients when compared with controls.
Photoreceptors are the most metabolically active neurons in
the central nervous system,25 although not usually regarded as
important in the pathogenesis of early DR, perhaps due in part
to the substantial distance between the photoreceptors and
the retinal microvasculature that is affected by diabetes.
However, a number of animal studies have reported that at
least some photoreceptors degenerate in DM.26–28 Further-
more, electrophysiology data suggest that photoreceptors and/
or RPE also show variable impairments in diabetes.29,30
The vasculopathy of the choriocapillary layer that nourishes
photoreceptors may be the cause of photoreceptor degener-
ation in diabetic patients. A diabetic choroidopathy in diabetic
eyes without DR was identified in histological, animal, and
human studies and characterized by changes in choroidal
blood flow, impaired autoregulation,31 and differences in the
CT measured by OCT32 accompanied by pathologic changes
like degenerative capillaries and capillary dropouts33 were
described. Therefore, it is possible that these microvascular
changes of the choroid may contribute to the photoreceptor
degeneration described in this study. A further possible cause
of photoreceptor degeneration may be the direct effects of
hyperglycemia and hypoinsulinemia. Diabetes mellitus changes
some elements in the insulin signalling pathway in the
photoreceptors, impairing the important survival and neuro-
protective signal.34,35
One interesting finding from our study was that the pattern
of thinning PR layer was not uniform throughout disease
FIGURE 3. Graphs showing retinal layer thickness in all groups, determined automatically by SD-OCT in nine ETDRS areas in the macula. (A) RT; (B)
RNFL; (C) GCL; (D) IPL; (E) INL; (F) OPL; (G) ONL; (H) PR; (I) RPE.
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duration, with patients with a moderate duration appearing to
have a smaller difference in thickness than both early and
longer known diabetes. This could be interpreted as a
temporary cellular swelling due to a number of reasons,
ranging from the diabetic-induced hypoxia,36 oxidative stress
with increased generation of superoxide, and other reactive
oxygen species in the retina,37 which induces the release of
proinflammatory molecules and changes in retinal vasculature.
Ultimately, the continuous cellular swelling is known to lead to
a cellular atrophy,36 potentially explaining the thinnest PR
layers in the patients with longer disease duration. This
nonlinear behavior is important, as it can explain the
contradictory results in this field, as each study may be
recruiting patients with a different disease duration. Addition-
ally, it could be clinically relevant, as studies have suggested the
importance of the PR layer in the development of DR, loss of
PR reduced the severity of vascular degeneration in DR.38,39
Further studies would be needed to interpret such findings.
The several clinical studies using SD-OCT to show changes
that correspond to an early neurodegenerative process in DR
typically analyzed the inner layers of the retina, and they either
showed a decreased RNFL or GCL thickness in diabetic
patients without DR17,40,41 or did not find differences in any
inner layer thickness between nondiabetic and type 1 or type 2
diabetic patients even without DR.15,16 Vujosevic and Midena17
studied both inner and outer layers but in opposition to this
work they did not find any differences in the RPE and PR layer
thickness. However, these authors have studied the RPE and PR
layers together not individualizing them in two different layers.
This study had some limitations. First, despite being one of
the largest studies in the field, including 125 diabetic patients
without DR, subdividing into smaller groups for disease
duration may have hampered our ability to subanalyze the
RT. Nevertheless, our main outcome was the analysis of the
overall RT between diabetic and nondiabetic subjects. Our
interesting data regarding the subgroup analysis can provide a
useful hint in future studies. Second, retinal measurements
were done with automatic software. However, a manual
correction was performed when the segmentation was
inaccurate by an ophthalmologist masked to the patients’
diagnosis. Third, our assumption for the length of disease
duration is dependent on the clinical diagnosis, which may
have underestimated the real time of diabetes.
In conclusion, diabetic patients without DR have a thinning
of the PR layer, when compared with a nondiabetic group.
There are early changes in outer retinal layers of diabetic
patients even without clinical signs of DR that probably
correspond to an inflammatory and apoptotic process of the
retina as a neurovascular unit.
Acknowledgments
Special thanks to orthoptist Gonc¸alo Agudo for his help in
obtaining tomographic images.
Disclosure: J. Tavares Ferreira, None; M. Alves, None; A. Dias-
Santos, None; L. Costa, None; B.O. Santos, None; J.P. Cunha,
None; A.L. Papoila, None; L. Abega˜o Pinto, None
References
1. Klein BEK. Overview of epidemiologic studies of diabetic
retinopathy. Ophthalmic Epidemiol. 2007;14:179–183.
2. International Diabetes Federation (IDF). IDF Diabetes Atlas.
7th ed. Available at: http://www.diabetesatlas.org/. Accessed
on June 3, 2016.
3. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and
major risk factors of diabetic retinopathy. Diabetes Care. 2012;
35:556–564.
4. Gardete-Correia L, Boavida JM, Raposo JF, et al. First diabetes
prevalence study in Portugal: PREVADIAB study. Diabet Med.
2010;27:879–881.
5. Dutra Medeiros M, Mesquita E, Papoila AL, Genro V, Raposo
JF. First diabetic retinopathy prevalence study in Portugal:
RETINODIAB Study—Evaluation of the screening pro-
gramme for Lisbon and Tagus Valley region. Br J Ophthal-
mol. 2015;99:1328–1333.
6. Dutra Medeiros M, Mesquita E, Gardete-Correia L, et al. First
incidence and progression study for diabetic retinopathy in
Portugal, the RETINODIAB study: evaluation of the screening







Dependent variable: PR layer thickness at sector S3
CT 0.005 0.096 0.001 0.011
Sex 0.339 0.373 0.404 1.082
Group I 2.096 < 0.001† 3.067 1.124
Group II 1.582 0.004 2.650 0.514
Group III 2.324 < 0.001† 3.450 1.197
Dependent variable: PR thickness at sector I3
CT 0.000 0.880 0.005 0.006
Gender 0.277 0.407 0.375 0.928
Group I 1.535 < 0.001† 2.374 0.695
Group II 0.720 0.131 1.650 0.211
Group III 1.744 < 0.001† 2.726 0.762
Dependent variable: PR layer thickness at sector T3
CT 0.005 0.181 0.002 0.012
Gender 0.131 0.753 0.684 0.946
Group I 2.059 < 0.001† 3.132 0.987
Group II 1.678 0.006 2.854 0.501
Group III 2.448 < 0.001† 3.684 1.213
Dependent variable: PR layer thickness at sector N3
CT 0.004 0.214 0.002 0.010
Gender 0.525 0.180 0.240 1.289
Group I 1.311 0.010 2.301 0.321
Group II 1.283 0.025 2.390 0.175
Group III 2.048 < 0.001† 3.203 0.894
Dependent variable: PR layer thickness at sector S6
Gender 0.354 0.290 0.300 1.008
Group I 1.685 < 0.001† 2.531 0.838
Group II 1.229 0.011 2.164 0.295
Group III 2.291 < 0.001† 3.282 1.301
Dependent variable: PR layer thickness at sector I6
Gender 0.364 0.248 0.250 0.978
Group I 1.293 0.002 2.091 0.494
Group II 0.842 0.062 1.719 0.035
Group III 1.456 0.003 2.387 0.524
Dependent variable: PR layer thickness at sector T6
Gender 0.351 0.297 0.307 1.009
Group I 1.704 < 0.001† 2.560 0.848
Group II 1.262 0.009 2.202 0.322
Group III 1.984 < 0.001† 2.981 0.986
Dependent variable: PR layer thickness at sector N6
Gender 0.582 0.050 0.004 1.160
Group I 1.569 < 0.001† 2.321 0.818
Group II 1.075 0.012 1.900 0.250
Group III 1.920 < 0.001† 2.797 1.044
P values were obtained by generalized additive regression models.
* Reference categories: female sex and nondiabetic group.
† Statistical significance using Bonferroni correction.
Retinal Neurodegeneration in Diabetic Patients IOVS j November 2016 j Vol. 57 j No. 14 j 6459
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935850/ on 10/24/2017
program for Lisbon region. Ophthalmology. 2015;122:2473–
2481.
7. Albany NY, Kassoff A, David Goodman A, et al.; Early Treatment
Diabetic Retinopathy Study Research Group. Grading diabetic
retinopathy from stereoscopic color fundus photographs—an
extension of the modified Airlie House classification. ETDRS
report number 10. Ophthalmology. 1991;98:786–806.
8. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG,
Gardner TW. Neural apoptosis in the retina during experi-
mental and human diabetes. Early onset and effect of insulin. J
Clin Invest. 1998;102:783–791.
9. Carrasco E, Herna´ndez C, Miralles A, Huguet P, Farre´s J, Simo´
R. Lower somatostatin expression is an early event in diabetic
retinopathy and is associated with retinal neurodegeneration.
Diabetes Care. 2007;30:2902–2908.
10. Carrasco E, Herna´ndez C, de Torres I, Farre´s J, Simo´ R.
Lowered cortistatin expression is an early event in the human
diabetic retina and is associated with apoptosis and glial
activation. Mol Vis. 2008;14:1496–1502.
11. Garcia-Ramı´rez M, Herna´ndez C, Villarroel M, et al. Interpho-
toreceptor retinoid-binding protein (IRBP) is downregulated at
early stages of diabetic retinopathy. Diabetologia. 2009;52:
2633–2641.
12. van Dijk HW, Verbraak FD, Stehouwer M, et al. Association of
visual function and ganglion cell layer thickness in patients
with diabetes mellitus type 1 and no or minimal diabetic
retinopathy. Vision Res. 2011;51:224–228.
13. Fischer MD, Huber G, Beck SC, et al. Noninvasive in vivo
assessment of mouse retinal structure using optical coherence
tomography. PLoS One. 2009;4:e7507.
14. Ceklic L, Maa´r N, Neubauer AS. Optical coherence tomogra-
phy fast versus regular macular thickness mapping in diabetic
retinopathy. Ophthalmic Res. 2008;40:235–240.
15. van Dijk HW, Verbraak FD, Kok PHB, et al. Early neurodegen-
eration in the retina of type 2 diabetic patients. Invest
Ophthalmol Vis Sci. 2012;53:2715–2719.
16. van Dijk HW, Verbraak FD, Kok PHB, et al. Decreased retinal
ganglion cell layer thickness in patients with type 1 diabetes.
Invest Ophthalmol Vis Sci. 2010;51:3660–3665.
17. Vujosevic S, Midena E. Retinal layers changes in human
preclinical and early clinical diabetic retinopathy support early
retinal neuronal and Mu¨ller cells alterations. J Diabetes Res.
2013;2013:905058.
18. van Dijk HW, Kok PHB, Garvin M, et al. Selective loss of inner
retinal layer thickness in type 1 diabetic patients with minimal
diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:
3404–3409.
19. Ctori I, Huntjens B. Repeatability of foveal measurements
using Spectralis optical coherence tomography segmentation
software. PLoS One. 2015;10:e0129005.
20. Simo´ R, Herna´ndez C. Neurodegeneration in the diabetic eye:
new insights and therapeutic perspectives. Trends Endocrinol
Metab. 2014;25:23–33.
21. DGS. Diagno´stico e Classificac¸a˜o da Diabetes Mellitus. Norma
da Direc¸a˜o Geral da Sau´de. 2011;2:1–13.
22. Jeoung JW, Kim T-W, Weinreb RN, Kim SH, Park KH, Kim DM.
Diagnostic ability of spectral-domain versus time-domain
optical coherence tomography in preperimetric glaucoma. J
Glaucoma. 2014;23:299–306.
23. Early Treatment Diabetic Retinopathy Study Research Group.
Photocoagulation for diabetic macular edema. Early Treatment
Diabetic Retinopathy Study report number 1 Arch Ophthal-
mol. 1985;103:1796–1806.
24. Spaide RF, Koizumi H, Pozzoni MC, Pozonni MC. Enhanced
depth imaging spectral-domain optical coherence tomogra-
phy. Am J Ophthalmol. 2008;146:496–500.
25. Ames A, Li YY, Heher EC, Kimble CR. Energy metabolism of
rabbit retina as related to function: high cost of Naþ transport.
J Neurosci. 1992;12:840–853.
26. Kumar B, Gupta SK, Srinivasan BP, et al. Hesperetin rescues
retinal oxidative stress neuroinflammation and apoptosis in
diabetic rats. Microvasc Res. 2013;87:65–74.
27. Park S-H, Park J-W, Park S-J, et al. Apoptotic death of
photoreceptors in the streptozotocin-induced diabetic rat
retina. Diabetologia. 2003;46:1260–1268.
28. Enzsoly A, Szabo A, Kantor O, et al. Pathologic alterations of
the outer retina in streptozotocin-induced diabetes. Invest
Ophthalmol Vis Sci. 2014;55:3686–3699.
29. Holfort SK, Jackson GR, Larsen M. Dark adaptation during
transient hyperglycemia in type 2 diabetes. Exp Eye Res. 2010;
91:710–714.
30. Harrison WW, Bearse MA, Ng JS, et al. Multifocal electroret-
inograms predict onset of diabetic retinopathy in adult
patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:
772–777.
31. Muir ER, Renteria RC, Duong TQ. Reduced ocular blood flow
as an early indicator of diabetic retinopathy in a mouse
model of diabetes. Invest Ophthalmol Vis Sci. 2012;53:6488–
6494.
32. Melancia D, Vicente A, Cunha JP, Abega˜o Pinto L, Ferreira J.
Diabetic choroidopathy: a review of the current literature.
Graefes Arch Clin Exp Ophthalmol. 2016;254:1453–1461.
33. Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris
degeneration and related pathologic changes in human
diabetic eyes. Arch Ophthalmol. 1998;116:589–597.
34. Rajala A, Dighe R, Agbaga M-P, Anderson RE, Rajala RVS.
Insulin receptor signaling in cones. J Biol Chem. 2013;288:
19503–19515.
35. Reiter CEN, Wu X, Sandirasegarane L, et al. Diabetes reduces
basal retinal insulin receptor signaling reversal with systemic
and local insulin. Diabetes. 2006;55:1148–1156.
36. Kern TS, Berkowitz BA. Photoreceptors in diabetic retinopa-
thy. J Diabetes Investig. 2015;6:371–380.
37. Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells
are major contributors to diabetes-induced oxidative stress
and local inflammation in the retina. Proc Natl Acad Sci U S A.
2013;110:16586–16591.
38. Arden GB. The absence of diabetic retinopathy in patients
with retinitis pigmentosa: implications for pathophysiology
and possible treatment. Br J Ophthalmol. 2001;85:366–370.
39. De Gooyer TE, Stevenson KA, Humphries P, Simpson DAC,
Gardiner TA, Stitt AW. Retinopathy is reduced during
experimental diabetes in a mouse model of outer retinal
degeneration. Invest Ophthalmol Vis Sci. 2006;47:5561–
5568.
40. Chhablani J, Sharma A, Goud A, et al. Neurodegeneration in
type 2 diabetes: evidence from spectral-domain optical
coherence tomography. Invest Ophthalmol Vis Sci. 2015;56:
6333–6338.
41. Carpineto P, Toto L, Aloia R, et al. Neuroretinal alterations in
the early stages of diabetic retinopathy in patients with type 2
diabetes mellitus. Eye (Lond). 2016;30:673–679.
Retinal Neurodegeneration in Diabetic Patients IOVS j November 2016 j Vol. 57 j No. 14 j 6460
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935850/ on 10/24/2017
